{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:24:49Z","timestamp":1787289889386,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.gore.2026.102155","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:02:26Z","timestamp":1782432146000},"page":"102155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immune checkpoint inhibitor\u2013induced encephalitis in endometrial carcinoma: Distinguishing immune from infectious causes"],"prefix":"10.1016","volume":"66","author":[{"given":"Laasyapriya","family":"Sarva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Alston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Delonais-Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon M.","family":"Grabosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2026.102155_bb0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of Cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"issue":"1","key":"10.1016\/j.gore.2026.102155_bb0010","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae186","article-title":"Immune-related encephalitis after immune checkpoint inhibitor therapy","volume":"30","author":"Buckley","year":"2025","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.gore.2026.102155_bb0015","first-page":"419","article-title":"Clinical features and outcomes of Myxedema coma in patients hospitalized for hypothyroidism: analysis of the United States National Inpatient Sample","volume":"34","author":"Chen","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.gore.2026.102155_bb0020","doi-asserted-by":"crossref","DOI":"10.1177\/11795549211056261","article-title":"Neurological adverse events induced by immune checkpoint inhibitors in non-small cell lung cancer: current perspectives and new development","volume":"15","author":"Cheng","year":"2021","journal-title":"Clin. Med. Insights Oncol."},{"issue":"23","key":"10.1016\/j.gore.2026.102155_bb0025","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.gore.2026.102155_bb0030","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/QCO.0000000000001121","article-title":"Urinary tract infections in immunocompromised patients","volume":"38","author":"Figueroa-Ortiz","year":"2025","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.gore.2026.102155_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90949-2","article-title":"Prospective cohort study on hospitalised patients with suspected urinary tract infection and risk factors por multidrug resistance","volume":"11","author":"Garcia-Bustos","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.gore.2026.102155_bb0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clim.2019.07.007","article-title":"West Nile virus infection triggering autoimmune encephalitis: pathophysiological and therapeutic implications","volume":"207","author":"Karagianni","year":"2019","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.gore.2026.102155_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.722586","article-title":"Case report: a variety of immune-related adverse events triggered by immune checkpoint inhibitors in a subject with malignant melanoma: destructive thyroiditis, aseptic meningitis and isolated ACTH deficiency","volume":"12","author":"Katakura","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.gore.2026.102155_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123286","article-title":"West Nile virus encephalitis: clinical characteristics and a comparison to other infectious encephalitides","volume":"467","author":"Maayan Eshed","year":"2024","journal-title":"J. Neurol. Sci."},{"issue":"23","key":"10.1016\/j.gore.2026.102155_bb0055","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.gore.2026.102155_bb0060","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2165\/00023210-200721100-00002","article-title":"Hashimoto\u2019s encephalopathy\u202f: epidemiology, pathogenesis and management","volume":"21","author":"Mocellin","year":"2007","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.gore.2026.102155_bb0065","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1212\/WNL.0000000000012122","article-title":"Autoimmune encephalitis related to Cancer treatment with immune checkpoint inhibitors: a systematic review","volume":"97","author":"Nersesjan","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.gore.2026.102155_bb0070","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.gore.2026.102155_bb0075","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1210\/clinem\/dgac689","article-title":"Approach to the patient with immune checkpoint inhibitor-associated endocrine dysfunction","volume":"108","author":"Wright","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.gore.2026.102155_bb0080","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-025-02822-1","article-title":"Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?","volume":"42","author":"Zamani","year":"2025","journal-title":"Med. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2026.102155_bb0085","article-title":"Co-occurrence of hypophysitis and thyroiditis induced by PD-L1 inhibitor avelumab: clinical insights","volume":"3","author":"Zavgorodneva","year":"2025","journal-title":"JCEM Case Rep."},{"issue":"2","key":"10.1016\/j.gore.2026.102155_bb0090","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10637-025-01511-0","article-title":"Clinical features, diagnosis, and treatment of pembrolizumab induced autoimmune encephalitis","volume":"43","author":"Zou","year":"2025","journal-title":"Investig. New Drugs"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:49:43Z","timestamp":1787287783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926001359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":18,"alternative-id":["S2352578926001359"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102155","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor\u2013induced encephalitis in endometrial carcinoma: Distinguishing immune from infectious causes","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102155"}}